UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1943-01-01
- Employees
- 8.1K
- Market Cap
- -
End-of-Life Care for African Americans: An Outpatient Intervention
Not Applicable
Completed
- Conditions
- Advance Care Planning
- Interventions
- Behavioral: Planning for the Care You Want
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 72
- Registration Number
- NCT03626402
- Locations
- 🇺🇸
Parkland Hospital, Dallas, Texas, United States
Phase I Study of Accelerated Hypofractionated Image-Guided Radiation Therapy
Not Applicable
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Radiation: Image-Guided Radiation Therapy
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 55
- Registration Number
- NCT03623334
Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Ketamine
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 43
- Registration Number
- NCT03621085
- Locations
- 🇺🇸
Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States
Vitamin D Homeostasis in Sarcoidosis
Phase 4
Recruiting
- Conditions
- SarcoidosisVitamin D Insufficiency
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT03621553
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas, United States
Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome
Phase 1
Withdrawn
- Conditions
- Cutaneous T-Cell Lymphomas
- Interventions
- Drug: TSEBT and pembrolizumabRadiation: TSEBT
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT03617224
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated With Radiation
Recruiting
- Conditions
- Cancer
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 10000
- Registration Number
- NCT03617237
- Locations
- 🇺🇸
UT Southwestern Medical Centre, Dallas, Texas, United States
Retrospective Review of Cachexia in Lung and Gastrointestinal Cancer Patients
Active, not recruiting
- Conditions
- Cachexia
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 20000
- Registration Number
- NCT03606317
Sildenafil Treatment for Mild TBI
Phase 2
Terminated
- Conditions
- Vascular System InjuriesConcussion, BrainPost-Concussion Syndrome
- Interventions
- Drug: Placebo oral capsuleDrug: Sildenafil Citrate
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 22
- Registration Number
- NCT03598140
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod
Not Applicable
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Device: Dose Fractionation
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 74
- Registration Number
- NCT03581136
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸UT Southwestern Medical Centre, Dallas, Texas, United States
ARQ761 + PARP Inhibitor in Refractory Solid Tumors
Phase 1
Withdrawn
- Conditions
- Lymphoma
- Interventions
- Drug: ARQ761, Olaparib
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT03575078
© Copyright 2025. All Rights Reserved by MedPath